Dyslipidaemia

@article{Durrington2003Dyslipidaemia,
  title={Dyslipidaemia},
  author={P. Durrington},
  journal={The Lancet},
  year={2003},
  volume={362},
  pages={717-731}
}
The lowering of serum cholesterol is increasingly recognised as essential in the prevention of coronary heart disease and other atherosclerotic disease. The success of statin trials and the need to deploy these drugs effectively in the population has led increasingly to the identification of many people whose serum cholesterol, triglycerides, and HDL-cholesterol require clinical assessment, and frequently treatment. Lipid disorders are mainly straightforward, but some are complex or resistant… Expand
53 Citations
Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing
  • M. Farnier
  • Medicine
  • Vascular health and risk management
  • 2008
  • 52
  • PDF
Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?
  • M. Farnier
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2007
  • 3
Apolipoprotein A5 and hypertriglyceridemia.
  • 27
  • PDF
Demystifying the management of hypertriglyceridaemia
  • 82
  • PDF
Monogenic pediatric dyslipidemias: classification, genetics and clinical spectrum.
  • 64
  • PDF
Statin policy and target populations: evidence-based or evidence-biased?
  • 3
Lipid Clinics Are Urgently Required in the Iranian Public Health System
  • 4
  • PDF
Gene therapy for genetic lipoprotein lipase deficiency: from promise to practice.
  • 27
...
1
2
3
4
5
...